ImmunityBio stock steadies near USD 8 after EU approval lifts Anktiva narrative

ImmunityBio stock remains volatile around USD 8 as investors weigh a strong year-to-date rally, recent EU approval for Anktiva in bladder cancer and latest quarterly figures showing higher revenue but a wider loss versus forecasts.

ImmunityBio stock (ISIN US45258J1025) is trading close to USD 8 as of September 4, 2026, after a sharp rally driven by growing sales of its bladder cancer therapy Anktiva and fresh regulatory milestones.

EU approval adds momentum to Anktiva

According to a report on September 5, 2026, shares of ImmunityBio have posted gains throughout the week, with the stock climbing nearly 1 percent on September 4, 2026 to reach its highest levels since May 2024, helped by optimism around its lead product Anktiva in bladder cancer.

The same coverage notes that ImmunityBio recently received European Union approval for Anktiva in combination with BCG for certain bladder cancer patients, clearing the therapy for use across all EU member states as well as Norway, Iceland and Liechtenstein, which broadens its commercial footprint beyond the United States.

Latest quarterly figures show revenue beat but wider loss

Fresh attention on ImmunityBio stock is also tied to its latest quarterly earnings report for 2026, which showed that the company generated revenue of USD 51.24 million in the period while posting a loss of USD 0.22 per share.

Market data compiled by a financial portal indicate that this USD 51.24 million in revenue exceeded analyst estimates for the quarter, whereas the loss of USD 0.22 per share was worse than the expected loss of USD 0.08 per share, highlighting a trade-off between top-line momentum and ongoing investment needs.

In a separate analysis published on September 4, 2026, ImmunityBio is described as having delivered record product revenues and a narrower adjusted loss than anticipated, with stronger-than-expected uptake of Anktiva contributing to the growth narrative.

Analyst view and valuation backdrop

Analyst sentiment around ImmunityBio remains constructive, with a consensus rating described as Moderate Buy and an average target price of USD 14.20 per share, compared with recent trading levels near USD 8.08 as of September 4, 2026, implying potential upside if execution and demand for Anktiva stay on track.

A valuation-focused review dated September 4, 2026 highlights that ImmunityBio’s year-to-date share price return stands at about 300 percent, while the one-year total shareholder return is reported around 236.67 percent, underscoring how strongly the stock has rerated as Anktiva moved from regulatory approval into commercial use.

The same analysis points to a fair value estimate of roughly USD 13 per share versus a last close of USD 8.08, suggesting that, even after the large rally, market expectations may still trail some longer-term growth scenarios built on expanding bladder cancer and broader immunotherapy indications.

Anktiva as a key commercial pillar

Anktiva, ImmunityBio’s immunotherapy for certain bladder cancer patients, is now a central driver of the company’s fundamentals, with product revenue benefiting from its approval for non-muscle invasive bladder cancer and growing physician adoption.

Industry commentary following the latest earnings release emphasizes that uptake of Anktiva is a major factor behind the record product revenues reported in the recent quarter, and that the newly secured European Union approval in combination with BCG opens further geographical markets that could reinforce momentum.

Stock volatility and current trading level

ImmunityBio stock trades on the Nasdaq under the ticker IBRX and has shown pronounced volatility, but recent price snapshots place it around USD 8.03 to USD 8.08 during intraday trading on September 4, 2026, with one dataset citing a move of about minus 1.34 percent on the day and another indicating a decline of about 4.29 percent earlier in the session.

Despite these short-term swings, commentary from market observers notes that ImmunityBio’s share price has been on a strongly positive trend throughout 2026, and that the stock is now trading close to levels discussed in several fair value assessments that cluster around USD 12.75 to USD 13 per share, providing a reference frame for investors analyzing risk and reward.

ImmunityBio at a glance

• Company: ImmunityBio, Inc.
• ISIN: US45258J1025
• Ticker: IBRX
• Trading venue: NASDAQ
• Price (as of September 4, 2026): 8.08 USD
• Market capitalization: 3.90 billion USD (as of September 4, 2026)
• Sector / Industry: Biotechnology / Immunotherapies
• Index membership: NASDAQ Composite